曲妥珠单抗生物仿制药治疗HER-2阳性乳腺癌的临床研究进展
Journal of Modern Oncology(2022)
Abstract
近年来,研究证明曲妥珠单抗可以显著改善人表皮生长因子受体-2(human epidermal growth-factor receptor 2,HER-2)阳性乳腺癌患者的生存预后,但由于其价格高昂,使患者选择受限.曲妥珠单抗生物仿制药的诞生有望节约成本、增加药物可及性,近年来已得到迅速发展.YL-1401O(Ogivri?)、CT-P6(Herzuma?)、SB3(Ontruzant?)、PF-05280014(Trazimera?)和ABP980(Kanjinti?),它们现已被美国食品药品监督管理局(Food and Drug Administration,FDA)批准用于HER-2阳性乳腺癌;我国HLX02已被欧洲药品管理局(The European Medicines Agency,EMA)和国家药品监督管理局(National Medical Products Administration,NMPA)批准上市.本文就近几年曲妥珠单抗生物仿制药在HER-2阳性乳腺癌中的研究进展进行综述,以期为HER-2阳性乳腺癌的靶向治疗提供参考.
MoreAI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined